Results for sars-cov-2

Add to feed Create your own feed


In preclinical studies, the vaccine induces a “a strong neutralizing antibody response plus potent and balanced T-cell response and against SARS-CoV-2, the virus that causes COVID-19,” Entos said.

NursingHomes: Learn how you can receive free training and mentorship to help prevent SARS-COV-2. #AHRQ  @TheIHI  @UNMHSC  #UnitedForNursingHomeSafety . More info here:

tweet picture

ICYMI #Nursing  Homes: See recent webinars about free training and mentorship to prevent SARS-COV-2. #AHRQ  @ProjectECHO  @TheIHI  Visit

tweet picture

$CVAC mRNA based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus neutralizing antibodies and mediates protection in rodents #COVID19 

"These results should act as a clarion call for more detailed research investigating the basis of cognitive deficits in people who have survived SARS-Cov-2 infection."

Existing government or private laboratories already approved by the ICMR for SARS-CoV-2 RT-PCR based testing may use this new CRISPR test.

Serum Institute of India and not-for-profit scientific research organisation IAVI have joined hands with science and technology company Merck to develop SARS-CoV-2 neutralising monoclonal antibodies

With the lack of public trust and confidence the biggest barrier to SARS-CoV-2 vaccines in the U.S., the risk of granting an EUA to a vaccine with safety issues or questionable efficacy could destroy confidence in future FDA-approved products.

$CVAC: CureVac announces data from preclinical studies of its investigational SARS-CoV-2 vaccine candidate, CVnCoV,...

$CVAC (+7.6%) announces data from preclinical studies of its investigational SARS-CoV-2 vaccine candidate, CVnCoV, in mice and hamsters


Most relevant

A 14-year-old has won $25,000 for a discovery that could provide a potential therapy to Covid-19. Anika Chebrolu's invention uses in-silico methodology to discover a lead molecule that can selectively bind to the spike protein of the SARS-CoV-2 virus.

I assessed the risk of Trump having infected Biden at the debate, based on what we know about how SARS-CoV-2 spreads, and how long it takes to be infectious or develop symptoms. (Yes, Biden tested negative today but that means little this early.)

Starting Tuesday, MIT is offering a weekly class to undergraduates **and the public** called “COVID-19, SARS-CoV-2 and the Pandemic.” An impressive lineup of guest speakers are coming. Livestream info here:

Two inoculations with a new SARS-CoV-2 mRNA-based vaccine that encodes a protein in the coronavirus spike elicited high titers of virus-neutralizing antibody in healthy adult volunteers. Virus-specific T-cell responses were also elicited. #COVID19  #SARSCoV2 

Quick tip on #COVID_19  terminology: *Coronavirus: family of viruses that cause, eg, common cold, MERS, SARS *Novel coronavirus: a newly discovered kind of coronavirus *COVID-19: the disease caused by the new coronavirus *SARS-CoV-2: official designation of virus causing COVID-19

More than 200 scientists have outlined evidence that they say shows the novel coronavirus can spread in tiny airborne particles, urging the @WHO  to update its guidance. Read our story on what we know so far about airborne transmission of SARS-CoV-2.

National Institute of Virology, Pune has successfully developed the 1st indigenous anti-SARS-CoV-2 human IgG ELISA test kit for antibody detection of #COVID19  . This robust test will play a critical role in surveillance of proportion of population exposed to #SARSCoV2  infection

tweet picture

In a first, Indian scientists have revealed a microscopy image of SARS-CoV-2 virus (COVID19). Scientists took the throat swab sample from first laboratory-confirmed COVID19 case in India, reported on Jan 30 in Kerala. The findings are published in the latest edition of the IJMR.

tweet picture

I wrote about the new coronavirus itself--where it came from, why it's behaving in the way it's behaving, how it infects and kills, and what the summer might bring. It's early days, of course, but this serves as a rough preliminary portrait of SARS-CoV-2.

Some not-horrible news on SARS-CoV-2 for once: It's mutating slowly considering how many people it has infected, which suggests a vaccine would be lasting, like vaccines for measles or chickenpox, rather than temporary like vaccines for flu. @JoelAchenbach